Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709602 · ClinicalTrials.gov registry record
SDH of HPV Vaccine Completion
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 3,076
- Enrollment target
NCT03709602: Completed study, sponsored by Duke University.
NCT03709602 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 3,076 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03709602 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 3,076 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out which factors influence parents' ability to complete the human papillomavirus (HPV) vaccine series for their child. The information learned from this study may help the investigators develop programs to improve HPV vaccine completion rates among adolescents and reduce barriers to receiving the second shot of the vaccine series.
Primary Outcome
Adolescents who completed the required HPV vaccine doses (e.g. two or three doses based on the CDC's vaccine administration guidelines for adolescents' ages 11 to 14 years) during the January 2017 to February 2019 observation period.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,076 participants |
| Start Date | 2019-01-07 |
| Est. Completion | 2019-12-17 |
What the finished NCT03709602 record still lists
NCT03709602 is an observational study that tracks outcomes without assigning an intervention. Its 3,076 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03709602 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03709602 about?
NCT03709602 is a clinical study titled "SDH of HPV Vaccine Completion". The purpose of this research study is to find out which factors influence parents' ability to complete the human papillomavirus (HPV) vaccine series for their child. The information learned from this study may help the investigators develop programs to improve HPV vaccine completion rates among adol...
What is the current status of trial NCT03709602?
This trial is currently completed. The enrollment target is 3,076 participants. The study started on 2019-01-07. Estimated completion is 2019-12-17.
Who is sponsoring clinical trial NCT03709602?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
- NCT05051722 · 3,110 participants
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI